StockNews.AI
SRPT
StockNews.AI
62 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

1. Pomerantz LLP investigates potential securities fraud involving Sarepta Therapeutics. 2. Sarepta's stock plummeted 27.44% after a patient's death linked to Elevidys. 3. A second death caused a 42.12% stock decline and halted Elevidys trials. 4. Investors are advised to join the class action regarding the allegations. 5. The firm has a history of fighting for victims of corporate misconduct.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The recent deaths and stock declines raise serious investor concerns. Historical patterns show significant price drops following negative news of drug safety issues.

How important is it?

The ongoing investigation and severe stock price reactions highlight significant risks for investors. Stakeholder impact and legal ramifications could greatly affect SRPT's future.

Why Short Term?

Immediate stock concerns are likely due to current investor sentiment and ongoing investigations. Similar past events caused substantial short-term drops in biotech stocks.

Related Companies

IBBXBI
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Sarepta and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On March 18, 2025, Sarepta issued a press release disclosing the death of “a young man with Duchenne muscular dystrophy . . . following treatment with ELEVIDYS”, Sarepta’s Duchenne muscular dystrophy drug, “having suffered acute liver failure.” On this news, Sarepta’s stock price fell $27.81 per share, or 27.44%, to close at $73.54 per share on March 18, 2025. Then, on June 16, 2025, Sarepta issued a press disclosing a second fatality from acute liver failure in a patient treated with Elevidys. As a results, Sarepta halted its ongoing clinical trial and temporarily suspended distribution of Elevidys for patients who are no longer able to walk. On this news, Sarepta’s stock price fell $15.24 per share, or 42.12%, to close at $20.94 per share on June 16, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes.    CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980

Related News